Clinical effect of sevelamer in hyperphosphatemia of chronic renal failure patients with maintenance hemodialysis / 药物评价研究

ABSTRACT

Objective To investigate the clinical effect of sevelamer in hyperphosphatemia of chronic renal failure patients with maintenance hemodialysis.Methods Chronic renal failure patients (80 cases) with maintenance hemodialysis and hyperphosphatemia m The First People's Hospital of Nanyang from July 2013 to August 2016 were selected and divided into observation group and control group,40 cases in each group.Patients in control group were treated with calcium acetate,and patients in observation group were treated with sevelamer.The effectiveness indexes (serum phosphorus,serum calcium,calcium-phosphorus product and iPTH),clinical effect,interleukin (IL) 6,tumor necrosis factor (TNF)-α,hypersensitive c-reactive protein (hs-CRP),and adverse reaction before and after treatment were compared.Results After treatment,the serum phosphorus and calcium-phosphorus product of two groups were significantly lower than before treatment (P ＜ 0.05),and the observation group were significantly lower than control group (P ＜ 0.05).After treatment,the total effective rate of the observation group was 92.50％,significantly higher than 75％ of the control group,and the difference was statistically significant (P ＜ 0.05).The levels of IL-6 and TNF-αt in two groups and hs-CRP level in observation group were significantly lower than those before treatment (P ＜ 0.05);The observation group was significantly lower than control group,and the difference between two groups was statistically significant (P ＜ 0.05).The difference in the adverse reaction rate had no significant between two groups.Conclusion Sevelamer Carbonate Tablets have remarkable clinical effect in hyperphosphatemia of chronic renal failure patients with maintenance hemodialysis,and can effectively reduce the serum levels of inflammatory cytokines,which is safe and reliable.